92 related articles for article (PubMed ID: 15488948)
21. Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy.
Stambas J; Brown SA; Gutierrez A; Sealy R; Yue W; Jones B; Lockey TD; Zirkel A; Freiden P; Brown B; Surman S; Coleclough C; Slobod KS; Doherty PC; Hurwitz JL
Vaccine; 2005 Mar; 23(19):2454-64. PubMed ID: 15752831
[TBL] [Abstract][Full Text] [Related]
22. Mutant hepatitis B virus surface antigens (HBsAg) are immunogenic but may have a changed specificity.
Zheng X; Weinberger KM; Gehrke R; Isogawa M; Hilken G; Kemper T; Xu Y; Yang D; Jilg W; Roggendorf M; Lu M
Virology; 2004 Nov; 329(2):454-64. PubMed ID: 15518823
[TBL] [Abstract][Full Text] [Related]
23. Immunoreactivity of HCV/HBV epitopes displayed in an epitope-presenting system.
Chen Y; Xiong X; Liu X; Li J; Wen Y; Chen Y; Dai Q; Cao Z; Yu W
Mol Immunol; 2006 Feb; 43(5):436-42. PubMed ID: 16337486
[TBL] [Abstract][Full Text] [Related]
24. Creating hybrid proteins by insertion of exogenous peptides into permissive sites of a class A beta-lactamase.
Ruth N; Quinting B; Mainil J; Hallet B; Frère JM; Huygen K; Galleni M
FEBS J; 2008 Oct; 275(20):5150-60. PubMed ID: 18793326
[TBL] [Abstract][Full Text] [Related]
25. Cationic transfersomes based topical genetic vaccine against hepatitis B.
Mahor S; Rawat A; Dubey PK; Gupta PN; Khatri K; Goyal AK; Vyas SP
Int J Pharm; 2007 Aug; 340(1-2):13-9. PubMed ID: 17446015
[TBL] [Abstract][Full Text] [Related]
26. Long-term persistence of hepatitis B surface antigen and antibody induced by DNA-mediated immunization results in liver and kidney lesions in mice.
Zi XY; Yao YC; Zhu HY; Xiong J; Wu XJ; Zhang N; Ba Y; Li WL; Wang XM; Li JX; Yu HY; Ye XT; Lau JT; Hu YP
Eur J Immunol; 2006 Apr; 36(4):875-86. PubMed ID: 16552712
[TBL] [Abstract][Full Text] [Related]
27. Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes.
Xu J; Ren L; Huang X; Qiu C; Liu Y; Liu Y; Shao Y
AIDS; 2006 Nov; 20(18):2293-303. PubMed ID: 17117015
[TBL] [Abstract][Full Text] [Related]
28. V3 CTL epitope density in a single recombinant molecule antigen differentially affects the number and activity of primary and memory CD8+ T cells.
Lu L; Zhu Y; Diao J; Wang Z; Chen YH
Vaccine; 2008 Feb; 26(6):845-52. PubMed ID: 18191003
[TBL] [Abstract][Full Text] [Related]
29. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target.
Manocha M; Pal PC; Chitralekha KT; Thomas BE; Tripathi V; Gupta SD; Paranjape R; Kulkarni S; Rao DN
Vaccine; 2005 Dec; 23(48-49):5599-617. PubMed ID: 16099080
[TBL] [Abstract][Full Text] [Related]
30. Limited cross-reactivity between different HIV-1 clades.
Mthunzi P; Meyer D
J Clin Virol; 2004 Dec; 31 Suppl 1():S88-91. PubMed ID: 15567099
[TBL] [Abstract][Full Text] [Related]
31. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS.
Gavioli R; Cellini S; Castaldello A; Voltan R; Gallerani E; Gagliardoni F; Fortini C; Cofano EB; Triulzi C; Cafaro A; Srivastava I; Barnett S; Caputo A; Ensoli B
Vaccine; 2008 Jan; 26(5):727-37. PubMed ID: 18096278
[TBL] [Abstract][Full Text] [Related]
32. Antibodies to hepatitis B surface antigen (HBsAg) elicited by immunization with a synthetic peptide covalently linked to liposomes.
Neurath AR; Kent SB; Strick N
J Gen Virol; 1984 May; 65 ( Pt 5)():1009-14. PubMed ID: 6202827
[TBL] [Abstract][Full Text] [Related]
33. Specificity of antibodies reactive with hepatitis B surface antigen following immunization with synthetic peptides.
Steward MW; Partidos CD; D'Mello F; Howard CR
Vaccine; 1993 Nov; 11(14):1405-14. PubMed ID: 7508664
[TBL] [Abstract][Full Text] [Related]
34. DNA vaccines prime CD8+ T cell responses to epitopes of viral antigens produced from overlapping reading frames of a single coding sequence.
Fissolo N; Riedl P; Reimann J; Schirmbeck R
Eur J Immunol; 2005 Jan; 35(1):117-27. PubMed ID: 15593127
[TBL] [Abstract][Full Text] [Related]
35. Ancestral and consensus envelope immunogens for HIV-1 subtype C.
Kothe DL; Li Y; Decker JM; Bibollet-Ruche F; Zammit KP; Salazar MG; Chen Y; Weng Z; Weaver EA; Gao F; Haynes BF; Shaw GM; Korber BT; Hahn BH
Virology; 2006 Sep; 352(2):438-49. PubMed ID: 16780913
[TBL] [Abstract][Full Text] [Related]
36. Optimisation of secretion of recombinant HBsAg virus-like particles: Impact on the development of HIV-1/HBV bivalent vaccines.
Michel M; Lone YC; Centlivre M; Roux P; Wain-Hobson S; Sala M
Vaccine; 2007 Feb; 25(10):1901-11. PubMed ID: 17005303
[TBL] [Abstract][Full Text] [Related]
37. Novel IgE peptide-based vaccine prevents the increase of IgE and down-regulates elevated IgE in rodents.
Peng Z; Liu Q; Wang Q; Rector E; Ma Y; Warrington R
Clin Exp Allergy; 2007 Jul; 37(7):1040-8. PubMed ID: 17581197
[TBL] [Abstract][Full Text] [Related]
38. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
Devadas K; Boykins RA; Hewlett IK; Wood OL; Clouse KA; Yamada KM; Dhawan S
Peptides; 2007 Mar; 28(3):496-504. PubMed ID: 17188401
[TBL] [Abstract][Full Text] [Related]
39. Cyclic V3-loop-related HIV-1 conjugate vaccines. Synthesis, conformation and immunological properties.
Tolman RL; Bednarek MA; Johnson BA; Leanza WJ; Marburg S; Underwood DJ; Emini EA; Conley AJ
Int J Pept Protein Res; 1993 May; 41(5):455-66. PubMed ID: 8320039
[TBL] [Abstract][Full Text] [Related]
40. Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins.
Grundner C; Pancera M; Kang JM; Koch M; Sodroski J; Wyatt R
Virology; 2004 Dec; 330(1):233-48. PubMed ID: 15527849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
